Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells

Leukemia Research

Volumn 39, Issue 1, 2015, Pages 65-71

  Nguyen, Tri ^a   Hawkins, Elisa ^a   Kolluri, Akhil ^a   Kmieciak, Maciej ^b   Park, Haeseong ^a   Lin, Hui ^a   Grant, Steven ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

BCR ABL; Bosutinib; Chk1 inhibitor; Chronic myeloid leukemia

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CD34 ANTIGEN; CELL PROTEIN; CYCLIN DEPENDENT KINASE 1; DASATINIB; DNA; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PF 00477736; PROTEIN BIMEL; PROTEIN MCL 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHECKPOINT KINASE 1; MAP2K1 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NITRILE; PIPERAZINE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN DEPHOSPHORYLATION; SURVIVAL TIME; UPREGULATION; AGONISTS; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; K562 CELL LINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MISSENSE MUTATION; NUDE MOUSE; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BENZODIAZEPINONES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; K562 CELLS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION, MISSENSE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITRILES; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZOLES; PYRIMIDINES; QUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920484411     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.10.009     Document Type: Article

References (37)

1. Quintas-Cardama A., Kantarjian H., Cortes J. Imatinib and beyond - exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009, 6(9):535-543.
2. Quintas-Cardama A., Kantarjian H., Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6(10):834-848.
3. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood 2007, 110(7):2242-2249.
4. Prasad V., Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA 2014, 311(4):353-354.
5. Branzei D., Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol 2010, 11(3):208-219.
6. Lobrich M., Jeggo P.A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 2007, 7(11):861-869.
7. Dai Y., Grant S. New insights into Chk kinase 1 in the DNA damage repair (DDR) signaling network: rationale for employing Chk1 inhibitors in cancer chemotherapy. Clin Cancer Res 2010, 16:376-383.
8. Syljuasen R.G., Sorensen C.S., Hansen L.T., Fugger K., Lundin C., Johansson F., et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005, 25(9):3553-3562.
9. Blasina A., Hallin J., Chen E., Arango M.E., Kraynov E., Register J., et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008, 7(8):2394-2404.
10. Fang D.D., Cao J., Jani J.P., Tsaparikos K., Blasina A., Kornmann J., et al. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line. Front Med 2013, 7(4):462-476.
11. Dai Y., Landowski T.H., Rosen S.T., Dent P., Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002, 100(9):3333-3343.
12. Dai Y., Yu C., Singh V., Tang L., Wang Z., McInistry R., et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001, 61(13):5106-5115.
13. Pei X.Y., Dai Y., Youssefian L.E., Chen S., Bodie W.W., Takabatake Y., et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 2011, 118(19):5189-5200.
14. Dai Y., Chen S., Shah R., Pei X.Y., Wang L., Almenara J.A., et al. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011, 117(6):1947-1957.
15. Dai Y., Chen S., Pei X.Y., Almenara J.A., Kramer L.B., Venditti C.A., et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced-DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008, 112(6):2439-2449.
16. Nguyen T.K., Rahmani M., Harada H., Dent P., Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007, 109(9):4006-4015.
17. Nguyen T., Dai Y., Attkisson E., Kramer L., Jordan N., Nguyen N., et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 2011, 17(10):3219-3232.
18. Nguyen T.K., Jordan N., Friedberg J., Fisher R.I., Dent P., Grant S. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res 2010, 34(3):379-386.
19. Nguyen T.K., Grant S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther 2014, 13(3):662-674.
20. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70(2):440-446.
21. Yu C., Dai Y., Dent P., Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. Cancer Biol Ther 2002, 1(6):674-682.
22. Ma C.X., Ellis M.J., Petroni G.R., Guo Z., Cai S.R., Ryan C.E., et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013, 137(2):483-492.
23. Hill B.G., Kota V.K., Khoury H.J. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther 2014, 1-6.
24. Syed Y.Y., McCormack P.L., Plosker G.L. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. BioDrugs 2014, 28(1):107-120.
25. Hoy S.M. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs 2014, 74(7):793-806.
26. Patil M., Pabla N., Dong Z. Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci 2013, 70(21):4009-4021.
27. Sausville E., Lorusso P., Carducci M., Carter J., Quinn M.F., Malburg L., et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 2014, 73(3):539-549.
28. Pei X.Y., Dai Y., Tenorio S., Lu J., Harada H., Dent P., et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood 2007, 110(6):2092-2101.
29. Moulding D.A., Quayle J.A., Hart C.A., Edwards S.W. Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 1998, 92(7):2495-2502.
30. Aichberger K.J., Mayerhofer M., Krauth M.T., Skvara H., Florian S., Sonneck K., et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005, 105(8):3303-3311.
31. Shimizu T., O'Connor P.M., Kohn K.W., Pommier Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 1995, 55(2):228-231.
32. Li W., Melton D.W. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 2012, 31(19):2412-2422.
33. Chakraborty S., Stark J.M., Sun C.L., Modi H., Chen W., O'Connor T.R., et al. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. Blood 2012, 119(26):6187-6197.
34. Takagi M., Sato M., Piao J., Miyamoto S., Isoda T., Kitagawa M., et al. ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia. DNA Repair (Amst) 2013, 12(7):500-507.
35. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432(7015):316-323.
36. Hubner A., Jaeschke A., Davis R.J. Oncogene addiction: role of signal attenuation. Dev Cell 2006, 11(6):752-754.
37. Sharma S.V., Gajowniczek P., Way I.P., Lee D.Y., Jiang J., Yuza Y., et al. A common signaling cascade may underlie addiction to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10(5):425-435.